MAR001 for High Triglycerides

(TYDAL-TIMI 78 Trial)

This trial tests a new treatment called MAR001 for individuals with high triglycerides, which are fats found in the blood. The goal is to determine how effectively MAR001 lowers triglyceride and remnant cholesterol levels compared to a placebo (a substance with no active drug). Participants will receive one of three different doses of MAR001 through an injection under the skin. Suitable candidates have high triglycerides and remnant cholesterol, maintain a stable diet, and can continue with their current medications. As a Phase 2 trial, this research focuses on measuring the treatment's effectiveness in an initial, smaller group of people.

The trial requires that you stay on a stable drug regimen, so you should not change your current medications during the study.

Earlier studies found MAR001 to be safe and generally well-tolerated. Researchers identified no serious side effects from the treatment. Participants showed no signs of swelling, irritation, or other concerning changes in the body. This suggests that MAR001 could be a safe option for individuals with high triglycerides, a type of fat in the blood.¹²³⁴⁵

Unlike the standard treatments for high triglycerides, which often rely on oral medications like statins or fibrates, MAR001 is administered via subcutaneous injection. Researchers are excited about MAR001 because it potentially offers a new mechanism of action, targeting triglyceride levels more directly and efficiently. The unique delivery method of MAR001 might also provide more consistent dosing and better patient compliance compared to daily pills. This innovative approach has the potential to significantly improve outcomes for patients struggling to manage their triglyceride levels.

Research has shown that MAR001 is promising in lowering high levels of triglycerides (a type of fat in the blood) and remnant cholesterol (leftover cholesterol in the blood after the body uses what it needs). In earlier studies, MAR001 reduced triglycerides by more than 50% compared to a placebo, and similar reductions in remnant cholesterol levels were observed. This suggests that MAR001 could help people with high triglycerides and remnant cholesterol. The treatment blocks a protein called ANGPTL4, which plays a role in how the body processes fat. Participants in this trial will receive one of three different doses of MAR001 to evaluate its effectiveness and safety.¹²³⁴⁶